Auriga Reiterates a 'Buy' on Medidata Solutions (MDSO); Not Getting Tangled, It's Still A Growth Story
Tweet
Share
E-mailGet Alerts MDSO Hot Sheet
Price: $92.22 --0%
Rating Summary:
5 Buy, 11 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
5 Buy, 11 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Auriga reiterates a 'Buy' on Medidata Solutions (NASDAQ: MDSO) price target of $33.00.
Auriga analyst said, "We are reiterating our rating and price target on MDSO on the heels of Q4 results in which revenue and EPS were roughly in line with expectations. The quarter was solid from a bookings standpoint, adding a record 25 customers for example, the revenue of which will become more pronounced in Q2. Meanwhile, consistent with our earnings preview last week, the strong backlog growth and revenue outlook of mid-high teens growth more than offset the EPS view, which was below consensus and our estimate. While it's easy to get tangled in intricacies of accounting relating to revenue acceleration, MDSO is sending the message across that this is very much a growth story. In a virtual duopoly with Oracle (Nasdaq: ORCL)(NotRated), MDSO is taking advantage of its competitors' missteps and exploiting what we envision as a significant market opportunity, particularly as its pharma customers crave solutions and approaches that drive operational efficiency. MDSO remains the top pick on our coverage list."
For an analyst ratings summary and ratings history on Medidata Solutions click here. For more ratings news on Medidata Solutions click here.
Shares of Medidata Solutions closed at $23.97 yesterday.
Auriga analyst said, "We are reiterating our rating and price target on MDSO on the heels of Q4 results in which revenue and EPS were roughly in line with expectations. The quarter was solid from a bookings standpoint, adding a record 25 customers for example, the revenue of which will become more pronounced in Q2. Meanwhile, consistent with our earnings preview last week, the strong backlog growth and revenue outlook of mid-high teens growth more than offset the EPS view, which was below consensus and our estimate. While it's easy to get tangled in intricacies of accounting relating to revenue acceleration, MDSO is sending the message across that this is very much a growth story. In a virtual duopoly with Oracle (Nasdaq: ORCL)(NotRated), MDSO is taking advantage of its competitors' missteps and exploiting what we envision as a significant market opportunity, particularly as its pharma customers crave solutions and approaches that drive operational efficiency. MDSO remains the top pick on our coverage list."
For an analyst ratings summary and ratings history on Medidata Solutions click here. For more ratings news on Medidata Solutions click here.
Shares of Medidata Solutions closed at $23.97 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
- Optimum Communications gets NYSE non-compliance notice over stock price
- Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS ViewRelated Entities
Auriga, EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
